Rivoceranib Mesylate
Who holds supplier records for Rivoceranib Mesylate? 1 organisation holds a current record for Rivoceranib Mesylate: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: China (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records
Cite as: PharmaTek, “Rivoceranib Mesylate: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/rivoceranib-mesylate
Reading the evidence
- One current record
One organisation holds a current DMF or CEP. A record shows a regulatory filing, not current commercial availability or a qualified source for your product.
- 1 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (1)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Rivoceranib Mesylate. Country is the organisation's recorded country, not necessarily the manufacturing site.
- JIANGSU HENGRUI PHARMACEUTICALS CO LTDChina Company GMP cert on recordActive DMF 37320 · latest filing Jan 2023
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Rivoceranib Mesylate is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL3545414).
Chemical identity
- IUPAC name
- N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid
- Canonical SMILES
- CS(=O)(=O)O.C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4
- InChIKey
- FYJROXRIVQPKRY-UHFFFAOYSA-N
- Synonyms
- Aitan, Apatinib mesylate, Apatinib (registered name in China), Rivoceranib mesylate, Yn-968d1, YN-968D1, Apatinib, YN968D1, RefChem:930792, Rivoceranib mesylate (USAN), RIVOCERANIB MESYLATE [USAN], YN 968D1
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Rivoceranib Mesylate?
1 organisation holds an active US FDA Type II Drug Master File or a CEP for Rivoceranib Mesylate: JIANGSU HENGRUI PHARMACEUTICALS CO LTD (China). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Rivoceranib Mesylate Drug Master Files are active?
JIANGSU HENGRUI PHARMACEUTICALS CO LTD (DMF 37320). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
How do I qualify a Rivoceranib Mesylate supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Rivoceranib Mesylate?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.